BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Biotech catalysts in 2026-09

221 industry Phase 2/3 trial readout(s) and 38 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.

← 2026-08 | 2026-10 →

FDA decision events

DateEventStatusCompanyDrugSource
2026-09-03FDA approvalapprovedHANDA ONCOLOMCAZIOApproved 2026-09-03: OMCAZIO (NDA220613 ORIG1)
2026-09-03FDA approvalapprovedIONIS PHARMS INC IONSZANVASTROApproved 2026-09-03: ZANVASTRO (NDA220210 ORIG1)
2026-09-04FDA approvalapprovedASTRAZENECA AZNETCAMAHApproved 2026-09-04: ETCAMAH (NDA220359 ORIG1)
2026-09-09Complete response lettercomplete responseSEIKAGAKU CorporationSI-6603 (condoliase) injectionCRL 2026-09-09: SEIKAGAKU Corporation BLA 761393 (SI-6603 (condoliase) injection)
2026-09-09FDA approvalapprovedBIOFRONTERA BFRIAMELUZApproved 2026-09-09: AMELUZ (NDA208081 SUPPL40)
2026-09-09FDA approvalapprovedBAYER HEALTHCAREHYRNUOApproved 2026-09-09: HYRNUO (NDA219972 SUPPL1)
2026-09-11FDA approvalapprovedSCHOLAR ROCK INC SRRKISEMBYLDApproved 2026-09-11: ISEMBYLD (BLA761463 ORIG1)
2026-09-11FDA approvalapprovedTELIX TLXPIXCLARAApproved 2026-09-11: PIXCLARA (NDA218592 ORIG1)
2026-09-11FDA approvalapprovedPHARMING PHARJOENJAApproved 2026-09-11: JOENJA (NDA217759 SUPPL6)
2026-09-14FDA approvalapprovedASTRAZENECA AZNTAGRISSOApproved 2026-09-14: TAGRISSO (NDA208065 SUPPL35)
2026-09-14FDA approvalapprovedCURIUMBEXLUTRYApproved 2026-09-14: BEXLUTRY (NDA218525 ORIG1)
2026-09-15FDA approvalapprovedEMERGE BIOSCIENCE PTE. LTD.GARZULYSApproved 2026-09-15: GARZULYS (BLA761497 ORIG2)
2026-09-16FDA AdComheldAdCom 2026-09-16: Pediatric Advisory Committee (PAC)
2026-09-16FDA approvalapprovedNUVATION NUVBIBTROZIApproved 2026-09-16: IBTROZI (NDA219713 SUPPL4)
2026-09-16FDA approvalapprovedBAYER HLTHCAREKERENDIAApproved 2026-09-16: KERENDIA (NDA215341 SUPPL11)
2026-09-16FDA approvalapprovedASTRAZENECA AZNTRUQAPApproved 2026-09-16: TRUQAP (NDA218197 SUPPL6)
2026-09-18FDA approvalapprovedELI LILLY AND CO LLYINLURIYOApproved 2026-09-18: INLURIYO (NDA218881 SUPPL1)
2026-09-18FDA approvalapprovedELI LILLY AND CO LLYVERZENIOApproved 2026-09-18: VERZENIO (NDA208716 SUPPL22)
2026-09-18FDA approvalapprovedINTRABIOAQNEURSAApproved 2026-09-18: AQNEURSA (NDA219132 SUPPL2)
2026-09-19PDUFA date (company-disclosed)date passedUltragenyx Pharmaceutical Inc. RAREapazunersenPDUFA September 19, 2026 - Ultragenyx Pharmaceutical Inc. (apazunersen)
2026-09-21FDA approvalapprovedMERCK SHARP DOHME MRKWINREVAIRApproved 2026-09-21: WINREVAIR (BLA761363 SUPPL12)
2026-09-22FDA approvalapprovedAGL WELDING SUPPLY CO INC DBA AGL GAS TECHNOLOGIESCARBON DIOXIDE USPApproved 2026-09-22: CARBON DIOXIDE, USP (NDA222000 ORIG1)
2026-09-23FDA AdComheldAdCom 2026-09-23: Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee
2026-09-23FDA approvalapprovedELEVARLYRFIGTUApproved 2026-09-23: LYRFIGTU (NDA220425 ORIG1)
2026-09-23FDA approvalapprovedELI LILLY AND CO LLYONSWIKApproved 2026-09-23: ONSWIK (BLA761408 ORIG1)
2026-09-24FDA approvalapprovedEISAI INCLENVIMAApproved 2026-09-24: LENVIMA (NDA206947 SUPPL35)
2026-09-24FDA approvalapprovedMERCK SHARP DOHME MRKWELIREGApproved 2026-09-24: WELIREG (NDA215383 SUPPL13)
2026-09-25FDA approvalapprovedABBVIE ABBVJUVMOApproved 2026-09-25: JUVMO; JUVMO (COPACKAGED) (NDA220415 ORIG1)
2026-09-25FDA approvalapprovedADVENTAPHARMAZUEINOApproved 2026-09-25: ZUEINO (NDA218379 ORIG1)
2026-09-25FDA approvalapprovedAZURITYLAMLIQUEApproved 2026-09-25: LAMLIQUE (NDA221109 ORIG1)
2026-09-25FDA approvalapprovedMIRUM MIRMATEBRIOZApproved 2026-09-25: ATEBRIOZ (NDA221198 ORIG1)
2026-09-25FDA approvalapprovedGENENTECHGAZYVAApproved 2026-09-25: GAZYVA (BLA125486 SUPPL43)
2026-09-25FDA approvalapprovedELI LILLY AND CO LLYOLUMIANTApproved 2026-09-25: OLUMIANT (NDA207924 SUPPL9)
2026-09-25FDA approvalapprovedTEVA PHARMACEUTICALS, INC. TEVADEGEVMAApproved 2026-09-25: DEGEVMA (BLA761481 ORIG1)
2026-09-28FDA approvalapprovedRARE THYROIDEMCITATEApproved 2026-09-28: EMCITATE (NDA220963 ORIG1)
2026-09-30FDA approvalapprovedBRISTOL BMYCAMZYOSApproved 2026-09-30: CAMZYOS (NDA214998 SUPPL13)
2026-09-30PDUFA date (company-disclosed)date passedAGIOS PHARMACEUTICALS, INC. AGIOPDUFA September 30, 2026 - AGIOS PHARMACEUTICALS, INC.
2026-09-30PDUFA date (company-disclosed)date passedScholar Rock Holding Corp SRRKPDUFA September 30, 2026 - Scholar Rock Holding Corp

Trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-09 est.P2/P3Medeor Therapeutics, Inc.NCT03605654 Cellular Immunotherapy in Recipients of Human Leukocyte Antigen (HLA)-Mismatched, Living Donor Kidney TransplantsKidney Transplant Rejectionwithdrawn
2026-09 est.P2Karyopharm Therapeutics Inc KPTIQNCT04562870 A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated MyelofibrosisMyelofibrosisactive not recruiting112
2026-09 est.P1/P2Clarity Pharmaceuticals LtdNCT04868604 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)Prostatic Neoplasms, Castration-Resistantrecruiting54
2026-09 est.P3Eidos Therapeutics, a BridgeBio companyNCT04882735 Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathywithdrawn
2026-09 est.P2Vasomune Therapeutics, Inc.NCT05123755 Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.Acute Respiratory Distress Syndrome; Viral or Bacterial Infections; Pneumonia; Pneumonia, Viral; Resactive not recruiting60
2026-09 est.P3Salutaris Medical Devices, Inc.NCT05251636 Adjunct Episcleral Brachytherapy for PCVAge-Related Macular Degeneration; Polypoid Choroidal Vasculopathynot yet recruiting159
2026-09 est.P3Alkermes, Inc. ALKSNCT05303064 Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I DisorderSchizophrenia; Bipolar I Disorderrecruiting220
2026-09 est.P1/P2Silence Therapeutics plc SLNNCT05499013 Study to Assess SLN124 in Patients With Polycythemia VeraPolycythemia Veraactive not recruiting69
2026-09 est.P2/P3REGENXBIO Inc. RGNXNCT05693142 AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)Duchenne Muscular Dystrophyactive not recruiting65
2026-09 est.P3CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.NCT05717764 Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent MetastaticRecurrent Metastatic Nasopharyngeal Carcinomanot yet recruiting500
2026-09 est.P1/P2Shanghai HyaMab Biotech Co.,Ltd.NCT05801237 PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid TumorLocally Advanced/Metastatic Solid Tumorsrecruiting120
2026-09 est.P1/P2Coordination Pharmaceuticals, Inc.NCT05838729 Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck CancerHead Neck Cancer; Intratumoral Injectionrecruiting16
2026-09 est.P2Repurposed Therapeutics, Inc.NCT05852730 Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor PerformanceMotion Sickness, Space; Motion Simulation; Parabolic Flightunknown80
2026-09 est.P1/P2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT05978284 Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine CarcinomaSmall Cell Lung Cancer; Neuroendocrine Carcinomarecruiting54
2026-09 est.P1/P2Hexaell Biotech Co., Ltd.NCT05989958 The Safety ,Tolerability and Efficacy Study of HepaCure in Chinese Subjects with Acute-On-Chronic Liver FailureAcute on Chronic Hepatic Failure; Liver Failure; Hepatitisrecruiting92
2026-09 est.P1/P2Georgiamune IncNCT06028074 Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid MalignanciesAdvanced Solid Malignanciesrecruiting111
2026-09 est.P3Clarity Pharmaceuticals LtdNCT06056830 Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical ProstatectomyProstate Cancer; Prostatic Neoplasmsrecruiting383
2026-09 est.P2Tourmaline Bio, Inc., a Novartis CompanyNCT06088979 A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye DiseaseThyroid Eye Diseaseactive not recruiting79
2026-09 est.P2Galmed Pharmaceuticals LtdNCT06095986 A Study Evaluating the Safety, Tolerability, and Efficacy of Aramchol Meglumine in Primary Sclerosing CholangitisPrimary Sclerosing Cholangitiswithdrawn
2026-09 est.P3AbbVie ABBVNCT06100744 A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) ReceiJuvenile Psoriatic Arthritisrecruiting40
2026-09 est.P2/P3Bio-Thera SolutionsNCT06123884 BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical CancerCervical Cancerrecruiting526
2026-09 est.P3Mabwell (Shanghai) Bioscience Co., Ltd.NCT06196736 A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial CancerAdvanced Urothelial Carcinomarecruiting432
2026-09 est.P1/P2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06452693 A Clinical Study to Evaluate the Efficacy of TQA3038 Injection in Patients With Chronic Hepatitis BHepatitis B, Chronicunknown162
2026-09 est.P3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06469879 A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer PatientsSmall Cell Lung Cancer Limited Stageunknown358
2026-09 est.P3Rophibio, Inc.NCT06470373 A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular DegenerationNeovascular Age-related Macular Degeneration (nAMD)not yet recruiting434
2026-09 est.P2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT06558227 Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular CarcinomaHepatocellular Carcinomaunknown90
2026-09 est.P3argenx ARGXNCT06742190 A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor NeuropathyMultifocal Motor Neuropathy (MMN); MMNactive not recruiting154
2026-09 est.P2Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT06767800 A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally AdvanGastroesophageal Adenocarcinomarecruiting204
2026-09 est.P2Cytokinetics CYTKNCT06793371 AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEFSymptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)recruiting60
2026-09 est.P2Maze Therapeutics MAZENCT06830629 A Phase 2 Study of MZE829 in Adults With APOL1 Kidney DiseaseProteinuric Kidney Diseaserecruiting74
2026-09 est.P3Jiangsu BioJeTay Biotechnology Co., Ltd.NCT06922045 Phase III Clinical Trial of STSP-0601 for Injection in Hemophilia PatientsHemophiliaactive not recruiting40
2026-09 est.P1/P2Jiangsu BioJeTay Biotechnology Co., Ltd.NCT06929299 A Phase Ib/II Clinical Trial of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Patients With Immune Thrombocytopenia (ITP)Primary Immune Thrombocytopenia (ITP)recruiting56
2026-09 est.P1/P2Qilu Pharmaceutical Co., Ltd.NCT06949761 A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced SoSolid Tumornot yet recruiting240
2026-09 est.P1/P2TYK Medicines, IncNCT06950086 Study of TYK-00540 Tablets in Patients With Advanced Solid TumorsHR-positive, HER2-negative Advanced Breast Cancerrecruiting180
2026-09 est.P2Nanjing Chia-tai Tianqing PharmaceuticalNCT06982040 Evaluate the Efficacy and Safety of NTQ5082 Capsules in Patients With Primary IgA NephropathyPrimary IgA Nephropathynot yet recruiting80
2026-09 est.P2NewAmsterdam Pharma NAMSNCT06982508 Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy VolunteersAntioxidant Absorptionrecruiting100
2026-09 est.P3Qilu Pharmaceutical Co., Ltd.NCT06994507 GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast CancerChemotherapy-induced Peripheral Neuropathy (CIPN)recruiting352
2026-09 est.P3Shandong Suncadia Medicine Co., Ltd.NCT07021976 A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic CardiomyopathyObstructive Hypertrophic Cardiomyopathyactive not recruiting228
2026-09 est.P2EIP Pharma IncNCT07033481 Clinical Study of Neflamapimod in Patients With Primary Progressive AphasiaNonfluent Variant Primary Progressive Aphasia (nfvPPA)active not recruiting20
2026-09 est.P3ScandiBio Therapeutics ABNCT07062198 Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's DiseaseAlzheimer Diseaserecruiting845
2026-09 est.P2Vanda Pharmaceuticals VNDANCT07065773 Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe OnychomycosisOnychomycosis of Toenailactive not recruiting50
2026-09 est.P2Fujian Shengdi Pharmaceutical Co., Ltd.NCT07100418 A Clinical Study Evaluating the Efficacy and Safety of HRS-7249 in Treating Patients With HyperlipidemiaHyperlipidemiaactive not recruiting224
2026-09 est.P2Vanda Pharmaceuticals VNDANCT07179055 An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry EyeDry Eyerecruiting160
2026-09 est.P2Guangdong Hengrui Pharmaceutical Co., LtdNCT07211542 A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic DermatitisModerate-to-severe Atopic Dermatitisrecruiting75
2026-09 est.P1/P2Corcept Therapeutics CORTNCT07276373 Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid MalignanciesNeoplasmsrecruiting50
2026-09 est.P2Biohaven Therapeutics Ltd. BHVNNCT07281495 Taldefgrobep Alfa in Adults With Overweight and ObesityObesity; Overweightactive not recruiting150
2026-09 est.P2Sinovac Life Sciences Co., Ltd.NCT07300644 Clinical Trial of PCV24 in Infants and Children Aged 2 Months to 5 YearsPneumococcal Infectious Diseaserecruiting420
2026-09 est.P2Sichuan Purity Pharmaceutical Technology Co., Ltd.NCT07304518 Phase II Trial of PRT-064040 Nasal Spray for the Treatment of Migraine in AdultsMigrainerecruiting456
2026-09 est.P2Fujian Shengdi Pharmaceutical Co., Ltd.NCT07318103 Phase II Clinical Study of HRS-9057 Injection in Patients With Heart Failure-induced Fluid RetentionFluid Retention Caused by Heart Failurerecruiting153
2026-09 est.P2Glaukos Corporation GKOSNCT07400965 Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex BlepharitisDemodex Blepharitisrecruiting250
2026-09 est.P1/P2Moogene Medi Co., LtdNCT07490327 Assessment of Dutasteride Topical Solution in Male Androgenetic AlopeciaAndrogenetic Alopecianot yet recruiting30
2026-09 est.P2R-Pharm International, LLCNCT07517575 Pharmacokinetics, Efficacy and Safety of Olokizumab In Patients With Juvenile Idiopathic ArthritisJuvenile Idiopathic Arthritisrecruiting71
2026-09 est.P3Colgate Palmolive CLNCT07664592 Comparative Efficacy of Different Dentin Occluding Toothpaste TechnologiesDentinal Sensitivity; Dentinal Hypersensitivityrecruiting132
2026-09 est.P2Shanghai Minwei Biotechnology Co., LtdNCT07804797 Phase 2 Study of MWN109 Tablet for Weight-Loss Maintenance in Participants With Overweight or ObesityOverweight , Obesityactive not recruiting71
2026-09-01 est.P3Incyte Corporation INCYNCT04824092 Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL PatientsDiffuse Large B-cell Lymphomaactive not recruiting899
2026-09-01 est.P2Beijing Continent Pharmaceutical Co, Ltd.NCT05689645 F573 for Injection for the Treatment of Liver Injury/FailureAcute Liver Failure; Acute-On-Chronic Liver Failurerecruiting97
2026-09-01 est.P1/P2Mabwell (Shanghai) Bioscience Co., Ltd.NCT05990452 Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid TumorsAdvanced Solid Tumoractive not recruiting261
2026-09-01P3UCB BIOSCIENCES, Inc.NCT06118255 A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet SyndromDravet Syndromecompleted25
2026-09-01 est.P2MedRegen LLCNCT06307522 MRG-001 in Patients With Alcoholic HepatitisAlcoholic Hepatitis; Acute Alcoholic Hepatitisnot yet recruiting32
2026-09-01P3Jiangsu HengRui Medicine Co., Ltd.NCT06569056 A Trial of HRS-8427 in the Treatment of Adults With Complicated Urinary Tract Infection, Including Acute PyelonephritisComplicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)completed579
2026-09-01 est.P3Daewoong Pharmaceutical Co. LTD.NCT06606093 Evaluate the Efficacy and Safety of DWP16001 in Type 2 Diabetic Nephropathy with Moderate Renal Impairment PatientsType 2 Diabetic Nephropathynot yet recruiting348
2026-09-01 est.P2Novo Nordisk A/S NVONCT06717698 A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney DiseaseChronic Kidney Diseaserecruiting465
2026-09-01 est.P2Tarian PharmaNCT06818058 TAR-0520 Gel in EGFR Inhibitor-induced FolliculitisEGFR Inhibitor-associated Rashrecruiting60
2026-09-01 est.P1/P2Zhejiang Teruisi Pharmaceutical Inc.NCT07035379 A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone(T-CHP) in Previously Untreated Patients With CD20-positive DLBCLDiffuse Large B-Cell Lymphoma (DLBCL)not yet recruiting66
2026-09-01P2Ethris GmbHNCT07059767 Phase IIa Trial in Participants With Asthma to Evaluate Impact of Intranasal ETH47 on Development of Asthma-related Symptoms Following Rhinovirus ChallengeAsthma (Diagnosis)completed50
2026-09-01 est.P1/P2MediLink Therapeutics (Suzhou) Co., Ltd.NCT07169994 A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid TumorsAdvanced Solid Tumors; Breast Cancer; Non Small Cell Lung Cancerrecruiting414
2026-09-02P2Il-Yang Pharm. Co., Ltd.NCT04691661 Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's DiseaseParkinson Diseaseactive not recruiting43
2026-09-02P3Kodiak Sciences Inc KODNCT06556368 A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-reWet Age-related Macular Degenerationactive not recruiting667
2026-09-02P1/P2SERDA bvNCT06628037 SN514-066b Enzyme in Deep Partial Thickness BurnsBurn Injuryterminated13
2026-09-02 est.P2Suzhou Alphamab Co., Ltd.NCT06747416 KN057 Multiple Dose Study in Patients with Hemophilia a or Hemophilia B with or Without InhibitorsHemophilia a and Bnot yet recruiting24
2026-09-03P1/P2Nacuity Pharmaceuticals, Inc.NCT05026632 NPI-002 Intravitreal Implant for the Delay of Cataract ProgressionCataractcompleted24
2026-09-03P3Novartis Pharmaceuticals NVSNCT05132075 Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung CancerNon-Small Cell Lung Cancerterminated95
2026-09-03P3Novo Nordisk A/S NVONCT05636176 A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and InflammationHeart Failureterminated4874
2026-09-03P2Hoffmann-La RocheNCT06965413 A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants WObesity; Overweight; Overweight With One Weight Related Comorbidityactive not recruiting285
2026-09-03P3AbbVie ABBVNCT07032597 A Study to Assess Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Restoration and/or Creation of Mid-Face Volume in Adult ParticipantsMid Face Volume Deficitcompleted252
2026-09-03P2AstraZeneca AZNNCT07218900 A Study to Investigate the Effect of AZD0780 Tablets in Combination With Rosuvastatin Tablets on Low Density Lipoprotein Cholesterol Levels (LDL-C) in Adult ParDyslipidaemiacompleted76
2026-09-04P3Vanda Pharmaceuticals VNDANCT04652882 Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)Sleep Wake Disorders; Sleep Disorders, Circadian Rhythm; Chronobiology Disorderscompleted43
2026-09-04P2Sanofi SNYNCT05039840 Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus ErythematosusSystemic Lupus Erythematosusactive not recruiting109
2026-09-04P3Cybin IRL LimitedNCT06564818 "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"Major Depressive Disordercompleted223
2026-09-04P3GlaxoSmithKlineNCT07596173 A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Healthy Japanese Adolescents Aged Diphtheria-Tetanus-acellular Pertussis Vaccinescompleted90
2026-09-05 est.P1/P2Bristol-Myers Squibb BMYNCT06730750 A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid TumorsAdvanced Solid Tumorsactive not recruiting360
2026-09-06 est.P2CastleVax Inc.NCT07215520 Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated AdultsCOVID-19active not recruiting200
2026-09-07P3Sarepta Therapeutics, Inc. SRPTNCT03992430 A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)Muscular Dystrophy, Duchennecompleted160
2026-09-07P2Edgewise Therapeutics, Inc. EWTXNCT05291091 Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)Becker Muscular Dystrophycompleted244
2026-09-07P2Arcus Biosciences, Inc. RCUSNCT05329766 A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract MalignancieGastrointestinal Tract Malignanciescompleted332
2026-09-07P2Merck Sharp & Dohme LLC MRKNCT07176390 A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)Arthritis, Rheumatoidactive not recruiting185
2026-09-08P3Alfasigma S.p.A.NCT02914535 Filgotinib in Long-Term Extension Study of Adults With Ulcerative ColitisUlcerative Colitiscompleted1173
2026-09-08P1/P2BlueSphere Bio, IncNCT06704152 BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDSAML, Adult Recurrent; ALL, Recurrent, Adult; MDSterminated2
2026-09-08P3Disc Medicine, Inc IRONNCT06910358 Study of Bitopertin in Participants With EPP or XLP (APOLLO)Erythropoietic Protoporphyria (EPP); X-Linked Protoporphyria (XLP)completed183
2026-09-08 est.P3Medprin Regenerative Medical Technologies Co., Ltd.NCT07830797 Absorbable Hemostatic Fluid Gelatin TrialSurgical Bleedingnot yet recruiting324
2026-09-09P2Gossamer Bio USA, Inc. GOSSNCT04816604 Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)Pulmonary Arterial Hypertensionterminated74
2026-09-09P2HB BioTech, LLCNCT06483789 Efficacy and Safety of HB-1 for Panic DisorderPanic Disorder; Mental Illnessterminated170
2026-09-09P3EyePoint Pharmaceuticals, Inc. EYPTNCT06683742 A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56Wet Age Related Macular Degeneration; wAMDactive not recruiting400
2026-09-09P2ViiV HealthcareNCT06741397 A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month DoHIV Infectionsactive not recruiting229
2026-09-09P1/P2BioInvent International ABNCT06784648 Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic MelanomaMelanoma Metastatic; Melanoma of Skin; Melanoma BRAF V600E/K Mutated; Melanoma Recurrent; Melanoma Sactive not recruiting35
2026-09-09P2Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsNCT07169942 Aleniglipron Phase 2 Body Composition StudyObesity, Overweight, or Chronic Weight Managementcompleted71
2026-09-09P2Kynexis B.V.NCT07191483 A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With SchizophreniaCognitive Impairment Associated With Schizophrenia (CIAS)completed149
2026-09-09P1/P2Umecrine Cognition ABNCT07304843 A Two-part Study to Investigate the Effects in Adults of Two Doses of Golexanolone in Patients With Primary Biliary Cholangitis (PBC) With Fatigue and CognitivePrimary Biliary Cholangitis (PBC)completed207
2026-09-10 est.P3Galaxy Therapeutics INC GLXYNCT05831202 SEAL™IT: Saccular Endovascular Aneurysm Lattice System Interventional Pivotal TrialIntracranial Aneurysmactive not recruiting279
2026-09-10P2GlaxoSmithKlineNCT06062420 A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma ofNeoplasms, Head and Neckactive not recruiting316
2026-09-10P1/P2Pfizer PFENCT06125522 TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-SBreast Cancerterminated11
2026-09-10P3Sanofi SNYNCT06208306 A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPDChronic Obstructive Pulmonary Diseasecompleted669
2026-09-10 est.P1/P2Shanghai Vitalgen BioPharma Co., Ltd.NCT06480461 A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R09b in Patients With Parkinson's DiseaseParkinson's Diseaseactive not recruiting39
2026-09-10 est.P3GlaxoSmithKlineNCT06855160 A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as IntramChickenpoxrecruiting911
2026-09-11 est.P3Priovant Therapeutics, Inc.NCT06431373 A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior UveitisUveitis, Posterior; Uveitis, Intermediate; Uveitisactive not recruiting371
2026-09-11P3Guangzhou Gloria Biosciences Co., Ltd.NCT06514508 Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma PatientsMultiple Myelomarecruiting60
2026-09-11P2Phathom Pharmaceuticals, Inc. PHATNCT06851559 A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 WeeksEosinophilic Esophagitisactive not recruiting95
2026-09-11P2Verdiva Bio Dev LimitedNCT07553299 A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related ComorbiditiesObesity; Overweight; Weight Maintenanceterminated8
2026-09-14P3Genzyme, a Sanofi CompanyNCT03754790 Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IXHemophiliacompleted281
2026-09-14P1/P2Cocrystal Pharma, Inc. COCPNCT07198139 A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CDI-988 in Healthy Adults After Challenge With Snow Mountain VirusNoroviruscompleted32
2026-09-15P1/P2BayerNCT03588299 Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Hemophilia Acompleted11
2026-09-15 est.P1/P2Wuhan YZY Biopharma Co., Ltd.NCT05543330 A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLCMalignant Pleural Effusions; NSCLC Stage IVrecruiting116
2026-09-15P2OM Pharma SANCT05857930 A Study to Assess the Efficacy and Safety of Daily OM-85 in Young Children With Recurrent WheezingRecurrent Wheezing; Wheezing Lower Respiratory Illnesscompleted296
2026-09-15 est.P2Thirty Respiratory LimitedNCT07073638 Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of RESP30TB in TuberculosisPulmonary Tuberculosesrecruiting24
2026-09-15 est.P2Estar Medical dba Medical Technologies, LTDNCT07318792 Using TropoCells(R) Autologous Platelet-Rich Fibrin (PRF) to Treat Chronic Non-Healing WoundsWound Chronic Draining; Wound Closurenot yet recruiting16
2026-09-15P2Shenzhen Salubris Pharmaceuticals Co., Ltd.NCT07835971 A Study to Evaluate Efficacy and Safety of GW906 in Patients With Essential HypertensionHypertensionactive not recruiting319
2026-09-16P1/P2Cellectis S.A. CLLSNCT04150497 Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)B-cell Acute Lymphoblastic Leukemiaactive not recruiting45
2026-09-16P2BioMarin Pharmaceutical BMRNNCT06668805 A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone TreatmentNoonan Syndrometerminated18
2026-09-16P2TBF Genie TissulaireNCT06723782 Surgical Release of Hand Tendons With Wrapping of the Released Tendon Using an Amniotic MembraneTendon Adhesion; Tenolysiscompleted18
2026-09-16P2Definium Therapeutics US, Inc. DFTXNCT07303907 A Phase 2A Trial of DT402 for Autism Spectrum DisorderAutism Spectrum Disorder; ASDcompleted5
2026-09-17P2Arcus Biosciences, Inc. RCUSNCT04736173 Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung CancerNon Small Cell Lung Cancer; Nonsquamous Non Small Cell Lung Cancer; Squamous Non Small Cell Lung Cancompleted169
2026-09-17P2Tiziana Life Sciences LTD TLSANCT06292923 A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis PatientsSecondary Progressive Multiple Sclerosiscompleted54
2026-09-17 est.P3Vertex Pharmaceuticals Incorporated VERXNCT06832410 An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney TransplantType 1 Diabetes; Kidney Transplantrecruiting10
2026-09-17P2Novartis Pharmaceuticals NVSNCT06857955 A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive PatientsHypertensionactive not recruiting396
2026-09-17P2Hoffmann-La RocheNCT07074886 A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)Multiple Sclerosisactive not recruiting193
2026-09-17P3Sarfez Pharmaceuticals, Inc.NCT07223502 A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With HypHypertension (HTN)withdrawn
2026-09-17P2Fujian Shengdi Pharmaceutical Co., Ltd.NCT07233070 HRS-7450 Injection Phase II Clinical Trial for Acute Ischemic Stroke.Acute Ischemic Strokecompleted210
2026-09-17P3Vaxcyte, Inc. PCVXNCT07284654 Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49Pneumococcal Diseasecompleted4049
2026-09-18P3Gan & Lee Pharmaceuticals.NCT06778967 A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)completed1133
2026-09-18P2Zura Bio Inc ZURANCT06993610 Tibulizumab Skin Healing and Inflammation Evaluation for Lasting DefenseHidradenitis Suppurativa (HS)active not recruiting247
2026-09-18P2Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsNCT07400588 Aleniglipron Phase 2 in Type 2 Diabetes MellitusObese; Obesity; Obesity Type 2 Diabetes Mellitus; Weight Losscompleted58
2026-09-20 est.P3Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.NCT07279194 Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without DiabetesObesity & Overweightrecruiting825
2026-09-20 est.P2/P3Bharat Biotech International LimitedNCT07555392 A Seamless Phase II/III, Observer-blind, to Evaluate Immunogenicity and Safety of Chikungunya Virus Vaccine in Healthy Subjects 12-65Years of Age.Active Immunisation for Chikungunya Virus Infectionrecruiting1000
2026-09-21 est.P3Cardiol Therapeutics Inc. CRDLNCT06708299 CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)Recurrent Pericarditisrecruiting110
2026-09-21P3AstraZeneca AZNNCT06750289 Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated Eosinophilic Asthmacompleted130
2026-09-21P2Aclaris Therapeutics, Inc. ACRSNCT07011706 ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic DermatitisAtopic Dermatitis; Atopic; Dermatitis; AD; Eczemaactive not recruiting110
2026-09-22P3Takeda TAKNCT04129502 TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion MutationsAdvanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)completed354
2026-09-22 est.P1/P2ImmVira Pharma Co. LtdNCT04370587 A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or MeSolid Tumor; Melanoma; HNSCC; Sarcoma; Squamous Cell Carcinoma; NSCLCrecruiting30
2026-09-22P1/P2Tango Therapeutics, Inc. TNGXNCT05887492 Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid TumorsNon Small Cell Lung Cancer; Solid Tumors, Adult; Lung Cancer; Lung Adenocarcinomaactive not recruiting126
2026-09-22P2BeOne Medicines ONCNCT05952037 A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström MacrogloWaldenstrom Macroglobulinemia; Waldenstrom's Macroglobulinemia Recurrent; Waldenstrom's Macroglobuliactive not recruiting114
2026-09-22P2Sanofi SNYNCT06033833 Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of PrevAsthmaterminated335
2026-09-22P2/P3Actinogen MedicalNCT06125951 Effect of 10 mg Xanamem on Dementia Due to Alzheimer's DiseaseDementia Moderate; Dementia, Mild; Alzheimer Diseaseactive not recruiting247
2026-09-22P2Jiangsu HengRui Medicine Co., Ltd.NCT06841731 A Trial of HRS-8427 in the Treatment of Adults With Bacterial PneumoniaHospital-acquired Bacterial Pneumonia (HABP); Ventilator-associated Bacterial Pneumonia (VABP)completed120
2026-09-22P2Vera Therapeutics, Inc. VERANCT07020923 Monthly Dosing of Atacicept in IgANIgA Nephropathy (IgAN); Berger Diseaseactive not recruiting90
2026-09-22P3Gan & Lee Pharmaceuticals.NCT07292441 Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight LossOverweight or Obesitycompleted224
2026-09-22P3BioNTech SE BNTXNCT07300839 A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of AgeCOVID-19; SARS-COV-2 Infectioncompleted5240
2026-09-22P2Samsung Bioepis Co., Ltd.NCT07844343 A Trial to Evaluate the Safety and Usability of the SB15 PFS in Trial Participants With AMD, Macular Oedema Secondary to RVO, or Diabetic Macular OedemaNeovascular Age-related Macular Degeneration; Macular Oedema Secondary to RVO; Diabetic Macular Oedecompleted33
2026-09-23P2Pfizer PFENCT05070845 Safety and Efficacy Study of PF-06835375 in Primary Immune ThrombocytopeniaPrimary Immune Thrombocytopeniaterminated61
2026-09-23P2Uniquity One (UNI)NCT06496620 A Study to Evaluate Solrikitug in Participants With COPD (ZION)COPDactive not recruiting182
2026-09-23P2Zenas BioPharma (USA), LLC ZBIONCT06559163 A Study of Obexelimab in Patients With Systemic Lupus ErythematosusSystemic Lupus Erythematosusactive not recruiting190
2026-09-23 est.P1/P2Sinocelltech Ltd.NCT06672536 Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMDnAMDrecruiting82
2026-09-23P3CSL BehringNCT06738485 Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII ProductsCongenital Hemophilia Acompleted62
2026-09-23P3Sanofi SNYNCT06834347 A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic RhinosinusiChronic Rhinosinusitis With Nasal Polypsactive not recruiting231
2026-09-23P2Innovent Biologics (Suzhou) Co. Ltd.NCT06937749 A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)Metabolic Dysfunction-associated Steatohepatitis (MASH)active not recruiting181
2026-09-23P2EIP Pharma IncNCT06987643 A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic StrokeModerate to Severe Acute Ischaemic Stroke; Ischaemic Strokecompleted45
2026-09-23P2Jiangsu Simcere Pharmaceutical Co., Ltd.NCT07175233 A Phase 2 Study to Evaluate the Efficacy, Safety of SIM0278 in Subjects With Moderate to Severe Atopic DermatitisAtopic Dermatitis (AD)active not recruiting184
2026-09-24P1/P2Novartis Pharmaceuticals NVSNCT05798117 An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus ErythematosusSystemic Lupus Erythematosus; Lupus Nephritiscompleted21
2026-09-24P2Ribocure Pharmaceuticals ABNCT06649266 Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of RBD1016 in Participants With Chronic Hepatitis DChronic Hepatitis Dactive not recruiting14
2026-09-24P3Sanofi SNYNCT06834360 A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic RhinosinusiChronic Rhinosinusitis With Nasal Polypsactive not recruiting216
2026-09-24 est.P2Innovent Biologics (Suzhou) Co. Ltd.NCT06862908 A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With ObesityObesity; Heart Failure With Preserved Ejection Fraction (HFPEF); Heart Failure With Mildly Reduced Eactive not recruiting141
2026-09-24P2CuraSen Therapeutics, Inc.NCT07089043 A Study in Subjects With Neurogenic Orthostatic HypotensionNeurogenic Orthostatic Hypotensionactive not recruiting12
2026-09-25P2Changchun BCHT Biotechnology Co.NCT07894055 A Phase II Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents)Pertussis (Whooping Cough); Diphtheria; Tetanusrecruiting420
2026-09-26 est.P2AstraZeneca AZNNCT06942910 A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease andChronic Kidney Disease With High Proteinuriaactive not recruiting224
2026-09-27 est.P3Biogen BIIBNCT04961567 A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus ErytheLupus Erythematosus, Systemicactive not recruiting562
2026-09-27 est.P1/P2Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT06864507 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HS-10561 Capsule in Healthy Chinese Adults and Patients With Chronic Chronic Spontaneous Urticarianot yet recruiting150
2026-09-28P3Regeneron Pharmaceuticals REGNNCT05133531 A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNHParoxysmal Nocturnal Hemoglobinuriacompleted202
2026-09-28P1/P2Novartis Pharmaceuticals NVSNCT05358249 Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationKRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small Cell Lung; Carcinoma, Non-Small-Cell Lung; Non-Sterminated74
2026-09-28 est.P3Bristol-Myers Squibb BMYNCT05552976 A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With RelapsRelapsed or Refractory Multiple Myelomaactive not recruiting606
2026-09-28P2Incyte Corporation INCYNCT05888844 A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell CarcinomaCutaneous Squamous Cell Carcinomaterminated63
2026-09-28 est.P2Attralus, Inc.NCT05951049 A Study of AT-02 in Subjects With Systemic Amyloidosis.Amyloidosis; Systemicactive not recruiting120
2026-09-28 est.P2/P3Ocugen OCGNNCT05956626 A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt DiseaseStargardt Diseaseactive not recruiting51
2026-09-28P3Chongqing Peg-Bio Biopharm Co., Ltd.NCT06512584 Efficacy and Safety of PJ009 in Patients With Short Bowel Syndrome Requiring Parenteral NutritionShort Bowel Syndromeactive not recruiting72
2026-09-28P3Incyte Corporation INCYNCT06516965 A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)Prurigo Nodularisactive not recruiting346
2026-09-28P3MoonLake Immunotherapeutics AG MLTXNCT06768671 An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis SuppuratHidradenitis Suppurativacompleted35
2026-09-28P3Cinclus Pharma Holding ABNCT07037875 A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux DiseaGERD (Gastroesophageal Reflux Disease)completed523
2026-09-29P1/P2Takeda TAKNCT02716116 A Study of TAK-788 in Adults With Non-Small Cell Lung CancerCarcinoma, Non-Small-Cell Lungcompleted324
2026-09-29P3Inventiva Pharma IVANCT04849728 A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 anNASH - Nonalcoholic Steatohepatitisactive not recruiting1000
2026-09-29P1/P2Pfizer PFENCT06924320 A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without DiabetesObesity and Obesity-related Medical Conditionscompleted201
2026-09-29P2Sanofi SNYNCT07222189 A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LColitis Ulcerative; Crohn's Diseaseterminated7
2026-09-30 est.P1/P2ImmunityBio, Inc. IBRXNCT02138734 A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder CancerNon-muscle Invasive Bladder Canceractive not recruiting369
2026-09-30 est.P2/P3SyneuRx International (Taiwan) CorpNCT03094429 An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an ARefractory Schizophreniarecruiting287
2026-09-30 est.P1/P2Turning Point Therapeutics, Inc. TPBNCT04094610 A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 AlterationsLocally Advanced Solid Tumors; Metastatic Solid Tumors; Lymphoma; Primary CNS Tumorsrecruiting75
2026-09-30P3GlaxoSmithKlineNCT04167358 Linerixibat Long-term Safety, and Tolerability StudyCholestasiscompleted242
2026-09-30 est.P3Hoffmann-La RocheNCT04603807 A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) WitCarcinoma, Non-Small-Cell Lungactive not recruiting217
2026-09-30 est.P3Biogen BIIBNCT04895241 A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus ErytheLupus Erythematosus, Systemicactive not recruiting548
2026-09-30 est.P3Innovent Biologics (Suzhou) Co. Ltd.NCT05116462 Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung CancerNon-Small Cell Lung Canceractive not recruiting506
2026-09-30 est.P3Beijing Continent Pharmaceutical Co, Ltd.NCT05288179 Efficacy and Safety of Pirfenidone Capsules in the Treatment of PneumoconiosisPneumoconiosisrecruiting272
2026-09-30P3Supergene, LLCNCT05372718 Thrombolysis With Recombinant Non-immunogenic Staphylokinase vs Surgery in Patients With Acute Limb Ischemia FORAT TrialAcute Limb Ischemiacompleted170
2026-09-30 est.P1/P2J Ints BioNCT05394831 A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLCEGFR Mutant Advanced Non-small Cell Lung Cancerrecruiting150
2026-09-30 est.P3AstraZeneca AZNNCT05557838 Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCCHepatocellular Carcinomaactive not recruiting214
2026-09-30 est.P2Mirati Therapeutics Inc.NCT05609578 Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C MutationAdvanced NSCLC; Metastatic Lung Canceractive not recruiting90
2026-09-30 est.P1/P2H. Lundbeck A/SNCT05669950 A Trial of Lu AG13909 in Participants With Congenital Adrenal HyperplasiaCongenital Adrenal Hyperplasiarecruiting42
2026-09-30P2Incyte Corporation INCYNCT05879822 A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor NaiveAdvanced Solid Tumorterminated73
2026-09-30 est.P1/P2Bristol-Myers Squibb BMYNCT05888831 A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid TumorsAdvanced Solid Tumorsactive not recruiting100
2026-09-30 est.P2Cantex PharmaceuticalsNCT05986851 Azeliragon in MGMT Unmethylated GlioblastomaGlioblastomaactive not recruiting30
2026-09-30 est.P3Beijing Pearl Biotechnology Limited Liability CompanyNCT05989542 A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)Non-small Cell Lung Cancerrecruiting136
2026-09-30 est.P1/P2Shanghai Pharmaceuticals Holding Co., LtdNCT06214156 A Clinical Study of T3011 in Subjects With Advanced MelanomaAdvanced Melanomarecruiting42
2026-09-30 est.P2Stamford Pharmaceuticals, Inc.NCT06344052 To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell CarcinomaBasal Cell Carcinomarecruiting80
2026-09-30 est.P2Convalife (Shanghai) Co., Ltd.NCT06374888 Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Her2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastanot yet recruiting28
2026-09-30P2Inozyme PharmaNCT06462547 ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 DeficiencyGene Mutations; Pseudoxanthoma Elasticum; Arterial Calcification; Ectonucleotide Pyrophosphatase/photerminated22
2026-09-30 est.P3GlaxoSmithKlineNCT06534892 An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age Respiratory Syncytial Virus Infectionsactive not recruiting10212
2026-09-30P1/P2Merck Sharp & Dohme LLC MRKNCT06637423 A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)Non-Muscle Invasive Bladder Cancercompleted35
2026-09-30 est.P3Shanghai JMT-Bio Inc.NCT06735391 A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic NonLocally Advanced or Metastatic Non-squamous NSCLC; Harboring EGFR Sensitive Mutations NSCLC; Previourecruiting516
2026-09-30 est.P2/P3Chongqing Claruvis Pharmaceutical Co., Ltd.NCT06783114 A Clinical Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in The Treatment of Upper Limb Spasticity in AdultsUpper Limb Spasticityrecruiting254
2026-09-30 est.P2Beijing Anlong Biopharmaceutical Co., Ltd.NCT06839339 Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMDWet Age-related Macular Degeneration (wAMD)not yet recruiting40
2026-09-30P3Vir Biotechnology, Inc. VIRNCT06903338 A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV InfectionViral Hepatitisactive not recruiting124
2026-09-30 est.P3CSPC Ouyi Pharmaceutical Co., Ltd.NCT06958692 A Trial of Dextromethorphan and Bupropion Sustained-Release Tablets in Patients With Major Depressive DisorderMajor Depressive Disorder (MDD)recruiting388
2026-09-30 est.P1/P2Innovent Biologics (Suzhou) Co. Ltd.NCT07000955 Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe ObesityObesityactive not recruiting98
2026-09-30 est.P2Tarian PharmaNCT07082764 Safety and Efficacy Study of TAR-0520 Gel in Prevention of Taxane-induced Peripheral NeuropathyChemotherapy Induced Peripheral Neuropathynot yet recruiting30
2026-09-30 est.P2Innovent Biologics (Suzhou) Co. Ltd.NCT07124793 A Study of IBI363 Combination Therapy in Participants With Advanced Solid TumorsEGFR Mutant NSCLC and Platinum Resistant Ovarian Cancernot yet recruiting60
2026-09-30 est.P2Cerus Corporation CERSNCT07155031 Biotin-Acridine Red Cell Exchange KineticsSickle Cell Diseasewithdrawn
2026-09-30 est.P2Graegis Pharmaceuticals LtdNCT07192588 A Study of GR1014 Cutaneous Gel for the Prevention of Skin Reactions Caused by Radiation Therapy for Breast CancerRadiodermatitis; Acuteactive not recruiting273
2026-09-30 est.P2Kahr Bio Australia Pty LtdNCT07235293 A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.Colorectal Cancerrecruiting90
2026-09-30 est.P2Hebei Senlang Biotechnology Inc., Ltd.NCT07244380 Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL.T Lymphoblastic Leukemia/Lymphomanot yet recruiting38
2026-09-30 est.P3Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.NCT07265284 A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque PsoriasisPsoriasisrecruiting104
2026-09-30 est.P2Shanghai Institute Of Biological ProductsNCT07327398 Phase Ⅱ Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and AboveInfluenzanot yet recruiting1200
2026-09-30P2Kylonova (Xiamen) Biopharma co., LTD.NCT07327840 Phase 2 Study of Kylo-11 in ASCVD Patients With Elevated Lp(a)Lipoprotein Disorderactive not recruiting204
2026-09-30 est.P2Joincare Pharmaceutical Group Industry Co., LtdNCT07351734 A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial of JKN2403 in COPDCOPD (Chronic Obstructive Pulmonary Disease)recruiting120
2026-09-30 est.P3UpTru Inc.NCT07356349 Study to Confirm the AuthenTicity of Point of Care Urine samplEs Using Oral fluoreScein Sodium in adulTs With substancE Use Disorder (ATTESTED)Substance Use Disorder (SUD)not yet recruiting114
2026-09-30 est.P1/P2EveryONE Medicines Inc.NCT07410143 Investigation of Individualised Antisense Oligonucleotides (ASOs) in People With Unique Genetic Variants Causing Severely Debilitating, Life Threatening (SDLT) Pediatric SDLT CNS Disordersactive not recruiting1
2026-09-30 est.P2AkesoNCT07436234 A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Seasonal Allergic RhinitisSeasonal Allergic Rhinitisnot yet recruiting111

← 2026-08 | 2026-10 →

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.